ClinicalTrials.gg
CompletedNCT01375543Updated Jan 6, 2020

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

An observational study in Genetic Predisposition, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-01-06.

Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
128
Sex
All
01

Study summary

Background:

- The purpose of this study is to identify changes in genes that cause human diseases. We would like to obtain some of you or your child s DNA and test for changes in genes that may contribute to a disease in you or your family.

Objective:

-To allow for exomic or genomic sequencing of NICHD patients or family members in order to identify changes in genes that cause or contribute to a specific disease.

Eligibility:

  • Children who are enrolled in an NICHD clinical study where the condition being studied may have a genetic cause.
  • Family members of a child who is eligible for this study.

Design:

  • Children and family members will supply DNA samples. If the samples are already available, no further DNA will be needed.
  • If DNA is not available, samples of either blood or skin will be taken.
  • We will use these samples with new DNA sequencing technology that looks at all the human genes we know about. This is known as exome and genome sequencing.
Read the detailed description

Over the last few years advancements in DNA sequencing technology have progressed significantly. It now is feasible and economical to sequence the exome (known genes) or the entire genome. This technological advance can be applied to identifying genetic causes of rare diseases where traditional methods such as mapping frequently failed due to insufficient number of cases. These cases often present themselves in the context of other NICHD research protocols, such as teaching protocols, where it would not be efficient for the individual investigators to write a new protocol. It will also serve to standardize the consent document across NICHD for investigators that do not include exomic/genomic sequencing in their own protocol.

02

Conditions studied

  • Genetic Predisposition

Keywords

  • Whole Exome
  • Whole Genome
  • Rare Disorders
  • Genetic Disorders
03

In context

Genetic Predisposition to Disease

238 studies on the registry are indexed under Genetic Predisposition to Disease; 91 are open to participants now.

This study's enrollment of 128 is below the median of 400 across 155 observational studies indexed under Genetic Predisposition to Disease.

Browse Genetic Predisposition to Disease studies →

Lead sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the lead sponsor of 422 studies on the registry; 25 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

-Children who are enrolled in an NICHD clinical study where the condition being studied may have a genetic cause.@@@-Family members of a child who is eligible for this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Proband s that are enrolled in an NICHD clinical protocol for which there is a suspicion of an underlying genetic cause for a disease for which they are being evaluated.

    1. Family members of a proband who is eligible for this protocol.

Exclusion criteria

EXCLUSION CRITERIA:

1. Normal volunteers unrelated to a proband with the disease of interest.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
128 participants (actual)

Groups and cohorts

  • Enrollees

    Enrolled study participants in whom genetic sequencing was done

06

What researchers measure

Primary outcomes

  1. Gene Mutations

    Identify genetic causes of rare diseases

    Time frame: Baseline, Continuously

Secondary outcomes

  1. Deidentified sequence data

    Allow NICHD investigators to access de-identified sequence data generated by the NICHD Molecular Genomics Laboratory

    Time frame: Baseline, Continuously

07

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Nov 2018, 89 months.

Of 79 non-industry observational studies under Genetic Predisposition to Disease, half reached primary completion within 118 months of starting (the median), counting those still running; a quarter within 50. This study's 89 months is below that.

Counting every sponsor, half of 81 studies reached it within 118 months; a quarter within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 17, 2011
StartActual
Jun 16, 2011
Primary completionActual
Nov 27, 2018
CompletionActual
Dec 31, 2019
Last update
Jan 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01375543
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Jun 16, 2011
Primary completion
Nov 27, 2018
Completion
Dec 31, 2019
Last update
Jan 6, 2020

Study contacts

An N Dang Do, M.D.
principal investigator · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion